In grade II glioma patients, Znf179 expression shown in two risk groups exhibited significant differences (p = 0.013) in clinical outcomes according to the Kaplan-Meier survival analysis (Fig. 5D). This evidence concerns the gene RNF112 and central nervous system cancer.